Search

Provider-listed inquiry route. Checked 2026-10-05. Bacterial infections evaluated by internal medicine, pediatrics, urology, gynecology and outpatient surgery specialists; isolate matching and individual assessment. Tbilisi; Georgia treatin

Research/development. Checked 2026-10-03. Phage research, collection, quality control and development; not listed as an additional patient intake clinic. Tbilisi; Georgia research-only GE Institute research contact info@pha.ge; use EPTC for

Research/development. Checked 2026-10-03. Microbiome gene editing and genetic-circuit delivery using phage-derived particles, including antibacterial CRISPR approaches. Paris; France company FR Corporate/research inquiry; no current patient

Research/development. Checked 2026-10-03. Phage discovery, research supply and development, including collaborations relevant to difficult infections. Exeter / Penryn; United Kingdom research-only GB University AMR research and phage collec

Official referral/inquiry route. Checked 2026-10-03. Current inquiries limited by funding to infections involving Pseudomonas aeruginosa or Staphylococcus aureus. Frankfurt am Main; Germany treating-center DE Official page gives phagenthera

Intake unconfirmed. Checked 2026-10-04. Laboratory support for resistant infections; historical pediatric CF/transplant-associated Mycobacterium abscessus treatment. London; United Kingdom supplier GB Official laboratory database lists phag

Official referral/inquiry route. Checked 2026-10-04. Multidisciplinary evaluation for exceptional compassionate use, notably difficult bone/joint and implant infections with serious functional or vital risk; matching supply and authorizatio

Intake unconfirmed. Checked 2026-10-03. Experimental individualized treatment after antibiotics/usual treatment fail; lab matching and manufacture. Helsinki; Finland treating-center FI HUS describes treatment coordinated by infectious disea

Official referral/inquiry route. Checked 2026-10-03. Outpatient experimental therapeutic protocol KB349/2005 for bacterial infections, including antibiotic-resistant infections. Wrocław; branches in Kraków and Częstochowa; Poland treating-c

Intake unconfirmed. Checked 2026-10-03. Documented difficult respiratory infection treatment, with additional pharmacy case experience. Geneva; Switzerland treating-center CH Institutional reports describe individual clinical treatment; no

Research/development. Checked 2026-10-03. Phage process development and manufacturing for human therapeutics, with fill/finish and other biologic services. Ljubljana; Slovenia supplier SI CDMO corporate contact info@jafral.com and commercia

Intake unconfirmed. Checked 2026-10-03. CF respiratory infection trial plans; clinical microbiology, Stockholm CF Center, infectious diseases and trauma/orthopedics collaboration. Stockholm; Sweden research-only SE Hospital innovation repor

Research/development. Checked 2026-10-03. DUOFAG topical phages for S. aureus and P. aeruginosa wounds/ulcers; official timeline reports Phase I completed July 2025, Phase IIA recruitment and Phase IIB approval February 2026. Prague; Czech

Intake unconfirmed. Checked 2026-10-03. Heart/thorax/transplant/vascular surgery experience with difficult bacterial infections; REPhRAME research partnership now includes MHH. Hannover; Germany treating-center DE Institutional reports docu

Research/development. Checked 2026-10-03. Engineered endolysins, including MEndoB for S. aureus-associated atopic dermatitis; phage-derived enzymes rather than live therapeutic phage preparations. Baar / Zurich; Bilthoven group activity; Sw

Provider-listed inquiry route. Checked 2026-10-03. Commercial bacteriophage preparations including Sextaphag, Intestiphag, Piophag, Staphilophag and Klebsiphag. Moscow; manufacturing sites including Perm; Russia supplier RU Current official

Provider-listed inquiry route. Checked 2026-10-03. Company describes a phage bank and registered pharmaceutical substances usable in magistral formulations; separately markets hygiene/cosmetic phage gels. Moscow; Russia supplier RU Manufact

Research/development. Checked 2026-10-03. Phage library, formulation/immobilization and human therapeutic development alongside other applications. Glasgow; United Kingdom company GB Official business/development inquiry; no current general

Intake unconfirmed. Checked 2026-10-03. Unlicensed physician-led use for difficult infections, including when antibiotics or surgery fail or cannot be used. Dundee; United Kingdom treating-center GB Scottish assessment describes an experime

Research/development. Checked 2026-10-03. Phage development for respiratory/systemic S. aureus including MRSA/MSSA and other staphylococcal infections. Dortmund; Germany company DE Official corporate inquiry info@phage-therapeutics.bio; no